GLP1-S (Injectable) dosing · Amino Reference

What it is

GLP1-S is a GLP-1 agonist. GLP-1 stands for glucagon-like peptide-1, a hormone that cells in your small intestine release after you eat. An "agonist" is something that copies a hormone and switches on the same targets it would. Natural GLP-1 helps control blood sugar, tells the brain you have eaten, and slows how fast the stomach empties.

GLP1-S is a man-made version of that hormone, redesigned so it lasts far longer in the body. That is why one injection a week is enough.

It was first approved by the FDA in 2017 for type 2 diabetes at doses up to 2.0 mg per week. In 2021 a higher-dose version at 2.4 mg per week was approved for long-term weight management, and in December 2025 an oral tablet at 25 mg daily was approved for weight management, the first swallowed GLP-1 medicine approved for obesity.

There is a huge amount of human research behind it. The STEP programme is a series of large trials with thousands of participants, and the SELECT heart trial alone enrolled over 17,000 people.

One thing worth knowing: GLP1-S switches on a single target, GLP-1. Newer compounds hit two (tirzepatide) or three (retatrutide). That matters when comparing results.

As a research product it arrives as a dry powder in a sealed glass vial. You add bacteriostatic water (sterile water with a preservative, so it keeps for weeks), then inject it just under the skin — a subcutaneous injection — once a week.

GLP1-S is a glucagon-like peptide-1 receptor agonist: a synthetic analogue of the incretin hormone released by L-cells of the small intestine after feeding, engineered for a dramatically extended duration of action so it can be dosed once weekly. Native GLP-1 governs glucose-dependent insulin secretion, appetite signalling and gastric motility.

Regulatory history: FDA approved in 2017 for type 2 diabetes at up to 2.0 mg weekly, in 2021 at 2.4 mg weekly for chronic weight management, and in December 2025 as an oral tablet at 25 mg daily for weight management — the first oral GLP-1 agonist approved for obesity.

The evidence base is among the largest in obesity medicine: the STEP Phase 3 programme enrolled thousands of participants across multiple trials, and the SELECT cardiovascular outcomes trial enrolled 17,604 patients.

Class position: GLP1-S is a single-receptor agonist. Tirzepatide is dual (GLP-1 and GIP), retatrutide triple (GLP-1, GIP and glucagon). In SURMOUNT-5 (Aronne et al., 2025), tirzepatide produced 20.2% weight loss versus 13.7% for GLP1-S at 72 weeks, while gastrointestinal discontinuation was higher with GLP1-S (5.6% versus 2.7%). Understanding what single-receptor agonism does and does not do is the key to placing it in the landscape.

Research-grade material is supplied as lyophilised powder, reconstituted in bacteriostatic water, administered subcutaneously once weekly.

How it works

GLP1-S switches on the same docking points in the body that natural GLP-1 uses. Those docking points sit in the brain, the pancreas, the stomach and the blood vessels, and each one produces a different effect.

Appetite, in the brain. This is the main driver of weight loss. Two brain areas are involved: the hypothalamus, which is the appetite control centre, and the nucleus of the solitary tract in the brainstem, which reads fullness signals coming up from the gut. GLP1-S turns up the nerve cells that say "I'm full" (POMC/CART neurons) and turns down the ones that say "I'm hungry" (NPY/AgRP neurons). It also dampens the reward value of food by changing dopamine signalling, the brain's pleasure chemistry. That is why people often say tempting foods simply stop pulling at them.

A slower stomach. GLP1-S weakens the muscular waves that push food out of the stomach and tightens the valve at the stomach exit. Food therefore sits longer. In one study, 37% of a solid meal was still in the stomach 4 hours later, compared with none in the placebo group. You feel full sooner and stay full.

Blood sugar. It boosts insulin release only when blood sugar is already high, and it reduces glucagon, the hormone that tells the liver to release stored sugar. Because the insulin effect only happens when sugar is up, GLP1-S rarely causes low blood sugar on its own.

Why once a week is enough. GLP1-S is 94% the same as human GLP-1, with three changes that stop the body breaking it down quickly and let it cling to albumin, the most common protein in blood. Over 99% of it travels bound to albumin. It stays around for about 7 days, and blood levels settle at a steady point after 4 to 5 weeks of consistent dosing. The swallowed version needs a special absorption helper and still only about 0.8% gets in, which is why the tablet dose is so much higher.

GLP1-S activates GLP-1 receptors distributed across the central nervous system, pancreas, stomach and cardiovascular system, with site-specific effects that combine into weight loss and metabolic improvement.

Central appetite regulation. GLP-1 receptors are concentrated in the hypothalamus and in the nucleus of the solitary tract (NTS) of the brainstem. Hypothalamic binding activates POMC/CART satiety neurons and indirectly inhibits orexigenic NPY/AgRP neurons. GLP1-S additionally reduces the hedonic value of food by modulating dopamine signalling in reward circuitry, which is the mechanistic basis for the reported collapse in food cue reactivity.

Gastric emptying. Antral contraction frequency and amplitude fall while pyloric sphincter tone rises, creating a functional outflow barrier. This is mediated partly through vagal afferents: GLP-1 receptors in the myenteric plexus activate adenylyl cyclase, raising cAMP and damping vagal cholinergic drive. One study found 37% of a solid meal retained at the 4-hour mark versus no retention on placebo.

Islet effects. Glucose-dependent amplification of insulin secretion plus suppression of glucagon release in the fed state, blunting postprandial hepatic glucose output. The glucose dependence is why monotherapy rarely produces hypoglycaemia.

Pharmacokinetics. GLP1-S is 94% structurally identical to native GLP-1 with three modifications: an alanine to alpha-aminoisobutyric acid substitution at position 8 conferring DPP-4 resistance; a lysine to arginine substitution at position 34 preventing unwanted acylation; and a C18 fatty diacid chain attached at position 26 via a linker, which drives albumin binding. Over 99% of circulating molecules are albumin-bound, shielding them from degradation and renal clearance. Half-life is approximately 7 days, steady state is reached after 4 to 5 weeks, and clearance occurs by proteolytic cleavage of the backbone and beta-oxidation of the fatty acid side chain, with metabolites excreted in urine and faeces. The oral formulation relies on the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) but achieves only about 0.8% bioavailability, hence the 25 mg daily oral dose against 2.4 mg weekly subcutaneous.

What it does

The headline effect is appetite. Hunger drops, meals end sooner, and fullness lasts. That is what creates the calorie deficit that produces fat loss.

Weight. In STEP-1, 1,961 adults with obesity and without diabetes took 2.4 mg weekly or placebo for 68 weeks. The GLP1-S group lost an average of 14.9% of body weight against 2.4% on placebo. 86% lost at least 5%, 69% lost at least 10%, and 50% lost at least 15%. In STEP-3, adding intensive behaviour therapy and an initial low-calorie diet gave 16.0% average loss at 68 weeks versus 5.7% with behaviour therapy alone, and about 40% of that group lost 20% or more. In STEP-5, 15.2% loss was still there at 2 years on continued treatment. For someone starting at 240 pounds, 15% is roughly 36 pounds.

Blood sugar. Fasting glucose and insulin sensitivity improve even in people without diabetes, and HbA1c falls meaningfully in people with type 2 diabetes. Some of that is from weight loss and some from the direct effect on insulin and glucagon.

Heart. The SELECT trial enrolled 17,604 patients aged 45 and over with existing heart disease and a BMI of 27 or above, but without diabetes. Over a mean follow-up of 39.8 months, GLP1-S cut the risk of major heart events — heart attack, stroke or cardiovascular death — by 20%.

Kidneys. In the FLOW trial, GLP1-S reduced the risk of important kidney outcomes by 24% in people with type 2 diabetes and chronic kidney disease over a median 3.4 years.

Other effects listed for this compound: potent anti-inflammatory action; reduced buildup of amyloid protein in the brain, the protein linked to Alzheimer's disease; potential in substance use disorders by reducing cravings; lower risk of complications from COVID-19; and fewer outbreaks of hidradenitis suppurativa, a chronic skin condition that causes painful lumps under the skin.

Primary action is central appetite suppression with prolonged satiety, generating an easier-to-sustain energy deficit.

Weight. STEP-1 (Wilding et al., 2021): 1,961 adults with obesity without diabetes, 14.9% mean body weight loss at 68 weeks on 2.4 mg weekly versus 2.4% placebo; 86% lost at least 5%, 69% at least 10%, 50% at least 15%. STEP-3 (Wadden et al., 2021): 16.0% at 68 weeks with intensive behavioural therapy and an initial low-calorie diet versus 5.7% for placebo plus behavioural therapy, with roughly 40% losing 20% or more. STEP-5 (Garvey et al., 2022): 15.2% maintained at 104 weeks.

Body composition. The exploratory DXA analysis of STEP-1 (140 participants) found total fat mass down 19.3% and visceral fat mass down 27.4%, with total lean body mass down 9.7% in absolute terms; lean mass as a proportion of total body mass rose by 3.0 percentage points. Roughly 60 to 65% of weight lost was fat, 35 to 40% lean. SEMALEAN (Alissou et al., 2025), 106 patients on 2.4 mg for 12 months: fat mass down 18% at 12 months, lean mass down 3 kg at 7 months then stabilising, handgrip strength up 4.5 kg at 12 months, and sarcopenic obesity prevalence falling from 49% to 33%.

Glycaemic. Improved fasting glucose and insulin sensitivity in non-diabetic populations; meaningful HbA1c reduction in type 2 diabetes, partly weight-independent via direct insulinotropic and glucagonostatic action.

Cardiovascular. SELECT (Lincoff et al., 2023): 17,604 patients aged 45 and older with established cardiovascular disease and BMI 27 or greater without diabetes; 20% reduction in MACE (hazard ratio 0.80, 95% CI 0.72 to 0.90, P < 0.001) over mean follow-up of 39.8 months.

Renal. FLOW: 24% reduction in clinically important kidney outcomes in type 2 diabetes with chronic kidney disease over a median 3.4 years, suggesting protection beyond that attributable to weight loss.

Also attributed to the compound: potent anti-inflammatory effects; reduced cerebral amyloid accumulation; craving reduction with demonstrated potential in substance use disorders, consistent with the reward-pathway component of GLP-1 signalling; lower risk of COVID-19-related complications; and reduced hidradenitis suppurativa flare frequency.

Benefits

Evidence grades: what the labels mean

Human trials Supported by randomised or placebo-controlled human trials.
Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
Animal or lab only Shown in animal or cell studies only; not yet tested in people.
Anecdotal No published studies; based on user reports or theory.

Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.

Suppresses appetite and produces a lasting feeling of fullness; food also becomes less interesting rather than harder to resist.Human trials
STEP-1: 14.9% average body weight loss at 68 weeks versus 2.4% on placebo, with 86% losing at least 5%, 69% at least 10% and 50% at least 15%.Human trials
STEP-3: 16.0% average loss at 68 weeks with intensive behaviour therapy, versus 5.7% with behaviour therapy alone; about 40% lost 20% or more.Human trials
STEP-5: 15.2% loss still held at 2 years with continued treatment.Human trials
Cuts fat more than lean tissue: in the STEP-1 DXA analysis, fat mass fell 19.3% and visceral fat 27.4%.Human trials
Reduces the risk of major cardiovascular events — heart attack, stroke or cardiovascular death — by 20% in adults with existing heart disease (SELECT, 17,604 patients).Human trials
Reduces important kidney outcomes by 24% in people with type 2 diabetes and chronic kidney disease (FLOW).Human trials
Improves fasting glucose and insulin sensitivity, and lowers HbA1c in type 2 diabetes.Human trials
Potent anti-inflammatory effects.Limited human data
Helps reduce the buildup of amyloid protein in the brain, a protein linked to Alzheimer's disease.Animal or lab only
Has shown potential in treating substance use disorders by reducing cravings.Human trials
Lowers the risk of complications from COVID-19.Limited human data
Fewer outbreaks of hidradenitis suppurativa, a chronic skin condition causing painful lumps under the skin.Limited human data

Central appetite suppression with sustained satiety plus reduced food reward salience via dopaminergic modulation.Human trials
STEP-1 (Wilding et al., 2021): 14.9% mean weight loss at 68 weeks versus 2.4% placebo; responder rates 86% at 5%, 69% at 10%, 50% at 15%.Human trials
STEP-3 (Wadden et al., 2021): 16.0% versus 5.7% at 68 weeks with intensive behavioural therapy; approximately 40% achieved 20% or greater loss.Human trials
STEP-5 (Garvey et al., 2022): 15.2% maintained at 104 weeks on continued treatment.Human trials
Favourable partitioning in the STEP-1 DXA analysis: fat mass down 19.3%, visceral fat down 27.4%, lean mass proportion up 3.0 percentage points.Human trials
SEMALEAN (Alissou et al., 2025): lean mass stabilised after 7 months, handgrip strength up 4.5 kg at 12 months, sarcopenic obesity prevalence down from 49% to 33%.Limited human data
SELECT (Lincoff et al., 2023): 20% MACE reduction (HR 0.80, 95% CI 0.72 to 0.90) in 17,604 patients with established cardiovascular disease without diabetes.Human trials
FLOW: 24% reduction in clinically important kidney outcomes in type 2 diabetes with chronic kidney disease.Human trials
Improved glycaemic regulation: fasting glucose, insulin sensitivity and HbA1c, partly independent of weight loss.Human trials
Potent anti-inflammatory effect.Limited human data
Reduced cerebral amyloid accumulation.Animal or lab only
Craving reduction with demonstrated potential in substance use disorders.Human trials
Lower risk of COVID-19-related complications.Limited human data
Reduced hidradenitis suppurativa flare frequency.Limited human data

What to expect

Timeline. Getting to the full weight loss dose takes about 16 to 17 weeks. Most people notice appetite suppression within the first 1 to 2 weeks, even on the starting dose. Weight loss usually begins in the second month as the dose climbs, and the biggest drop happens between months 3 and 9. In STEP-5 the curve flattened somewhere around 12 to 15 months at roughly 15% loss, and that was held through the 2-year study with continued dosing. Users commonly report 8 to 18% body weight reduction within 6 to 12 months.

It does not burn fat. This is the most important thing to understand. GLP1-S has no mechanism to burn fatty acids or raise your metabolic rate. Every pound lost comes from eating less than the body burns. The drug makes that deficit easy to hold because you are not fighting hunger all day. You still have to be in the deficit.

Side effects in practice. Nausea is the most talked-about problem, and it is worst in the first 1 to 2 weeks after each dose increase, then fades. Eating smaller meals, avoiding fatty food, staying hydrated and not lying down after eating all help. Constipation is reported nearly as often; fibre, magnesium and water help but do not always fix it. Fatigue is common in the first few months and is often down to eating too little food and too little protein rather than the drug itself. Sulfur-smelling burps are a known quirk, thought to come from food sitting in the stomach. Rapid weight loss also thins facial fat, which is where the "Ozempic face" talk comes from.

Muscle. Many people who train report feeling weaker and losing definition, especially when protein intake drops. Those with the best outcomes describe aggressive protein targets — at least 1 gram per pound of goal body weight — plus regular resistance training, treated as non-negotiable even when eating feels like a chore.

Stopping. When the drug stops, the appetite suppression stops. In the STEP-1 extension, participants who had lost an average of 17.3% regained two-thirds of it within one year, finishing with a net 5.6% loss from baseline. That is not a failure of the drug; the drivers of overeating simply return. Use the window to build the eating and training habits that hold the result.

Timeline. Titration to the 2.4 mg maintenance dose takes approximately 16 to 17 weeks. Appetite suppression is typically apparent within 1 to 2 weeks even at 0.25 mg. Weight loss generally begins in month 2 as the dose escalates, with the steepest phase between months 3 and 9. STEP-5 showed most reduction in year one with a plateau around 12 to 15 months at approximately 15%, maintained through 104 weeks on continued dosing. Aggregated user reports describe 8 to 18% body weight reduction within 6 to 12 months.

No thermogenic component. GLP1-S does not oxidise fatty acids or raise metabolic rate. The entire effect is intake-side: it lowers the behavioural cost of maintaining an energy deficit. This is also why discontinuation behaves the way it does.

Tolerability trajectory. Nausea is dose-dependent and peaks in the 1 to 2 weeks following each titration step before attenuating; about 4.5% of STEP-1 participants discontinued for gastrointestinal reasons. Constipation is reported nearly as frequently, managed in practice with magnesium citrate, fluid and fibre. Fatigue in the early months is frequently attributable to inadequate energy and protein intake rather than a direct drug effect. Sulfurous eructation is attributed to delayed gastric emptying. Pronounced facial fat loss tracks the speed of total weight loss rather than being compound-specific. Telogen effluvium was reported at 2.5% versus 1.0% on placebo and scales with the magnitude of loss.

Lean mass. Expect 35 to 40% of weight lost to be lean tissue without countermeasures. Resistance training 2 to 3 days per week and at least 1 gram of protein per pound of goal body weight materially shifts that ratio; a published case series documented one patient losing 33% of body weight with only 6.9% muscle loss and another gaining 2.5% muscle while losing 26.8% body weight, both with consistent training and protein.

Discontinuation. The STEP-1 extension (Wilding et al., 2022) followed 327 participants for one year after stopping both drug and lifestyle intervention: two-thirds of the average 17.3% loss was regained, leaving a net 5.6% from baseline. The pharmacology worked as designed; the appetite drivers returned and the habit scaffolding was absent.

Reconstitution and dosing

GLP1-S is injected under the skin once a week, on the same day each week. You can move the day as long as the last dose was at least 2 days before.

Studied doses. All the weight loss data comes from 2.4 mg weekly. The diabetes dose runs 0.5 to 2.0 mg weekly. The oral weight management dose is 25 mg daily.

The ladder. The dose steps up every 4 weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then 2.4 mg from week 17 onward. Do not skip steps. Starting high causes severe nausea and vomiting. If side effects are strong at any step, stay there for another 4 weeks before going up.

For type 2 diabetes the pattern is different: 0.25 mg for weeks 1 to 4, then 0.5 mg from week 5 onward, with an increase to 1.0 or 2.0 mg depending on response.

You may not need the top dose. The 2.4 mg target comes from trial protocols built to show maximum effect. In practice many people do very well lower down, and some lose significant weight at 1.0 mg with few side effects. Pushing to 2.4 mg can add side effects without adding proportional benefit. What suits you depends on how much weight you need to lose, how strongly the appetite suppression hits you, how well you cope with the gut side effects, and whether the goal is metabolic health or large weight loss.

Mixing. Research-grade powder comes in several vial sizes: 5 mg, 10 mg, 20 mg and 30 mg. Adjust the amount of bacteriostatic water to reach the concentration you want, and refrigerate after mixing. A common pairing is 5 mg with 1 mL (100 units) of bacteriostatic water and 10 mg with 2 mL (200 units); both give the same strength, so the draw for any given dose is identical. "Units" means the marks on an insulin syringe — 100 units is 1 mL. Some users step in smaller 0.25 mg increments up to 2.5 mg and stay at least four weeks on each step.

If you are prone to side effects, injecting before bedtime is a common choice, so the worst of the nausea overlaps with sleep.

Subcutaneous, once weekly, fixed day. The dosing day can be shifted provided the previous dose was at least 2 days prior.

Studied doses. The weight loss dataset derives entirely from 2.4 mg weekly subcutaneous as used in the STEP trials. The type 2 diabetes range is 0.5 to 2.0 mg weekly. The oral weight management dose is 25 mg daily. All were established through formal dose-finding work and confirmed in Phase 3.

Titration. Escalation every 4 weeks: 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg from week 17 as the maintenance dose. Steps are not skippable — initiating at higher doses produces severe nausea and vomiting. Where tolerability is poor at a given step, hold for a further 4 weeks before escalating; gastrointestinal burden is escalation-rate dependent. The diabetes schedule is 0.25 mg for weeks 1 to 4 then 0.5 mg from week 5, escalating to 1.0 or 2.0 mg by response.

Maximum dose is not obligatory. The 2.4 mg target reflects trial design aimed at demonstrating maximal effect. Many respond well below it and some achieve significant loss at 1.0 mg with minimal side effects; forcing 2.4 mg can add toxicity without proportional benefit. Dose selection depends on the magnitude of loss required, sensitivity to appetite suppression, gastrointestinal tolerance, and whether the objective is metabolic health or substantial weight reduction.

Reconstitution. Research-grade lyophilised powder is supplied in 5 mg, 10 mg, 20 mg and 30 mg vials; bacteriostatic water volume is adjusted to the desired concentration and the vial is refrigerated after reconstitution. A conventional pairing is 5 mg in 1 mL and 10 mg in 2 mL, both yielding 5 mg/mL, so draw volume for a given dose is identical between presentations. A slower alternative ladder in 0.25 mg increments to 2.5 mg weekly, with a minimum of four weeks at each step, is also used in practice.

Timing. Bedtime administration is used by side-effect-prone users so the peak nausea window falls during sleep.

Concomitant therapy. Insulin or sulfonylurea doses may require reduction on initiation to avoid hypoglycaemia; this needs medical supervision.

Standard, 5 mg vial

Mix with 1 mL (100 units) of bacteriostatic water.

5 mg/mL · 50 mcg per unit

Frequency: Once weekly, same day each week; subcutaneous. Dose increases every 4 weeks. Hold a step for an additional 4 weeks if side effects are strong. If prone to side effects, dose before bedtime

When	Dose	Draw	How often
Weeks 1 to 4	0.25 mg (starting dose)	5 units	once weekly
Weeks 5 to 8	0.5 mg	10 units	once weekly
Weeks 9 to 12	1.0 mg	20 units	once weekly
Weeks 13 to 16	1.7 mg	34 units	once weekly
Week 17 onward	2.4 mg (full weight loss maintenance dose)	48 units	once weekly

Alternative protocols

Alternative protocols reflect older community practice and are kept for reference.

Alternative, 5 mg vial

Mix with 1 mL (100 units) of bacteriostatic water.

5 mg/mL · 50 mcg per unit

Frequency: Once weekly, same day each week; subcutaneous. If prone to side effects, take the dose before bedtime

When	Dose	Draw	How often
0.25 mg	250 mcg	5 units	once weekly
0.5 mg	500 mcg	10 units	once weekly
0.75 mg	750 mcg	15 units	once weekly
1 mg	1 mg	20 units	once weekly
1.25 mg	1.25 mg	25 units	once weekly
1.5 mg	1.5 mg	30 units	once weekly
1.75 mg	1.75 mg	35 units	once weekly
2 mg	2 mg	40 units	once weekly
2.25 mg	2.25 mg	45 units	once weekly
2.5 mg	2.5 mg	50 units	once weekly

Alternative, 10 mg vial

Mix with 2 mL (200 units) of bacteriostatic water.

5 mg/mL · 50 mcg per unit

Frequency: Once weekly, same day each week; subcutaneous. Remain on each dose for a minimum of 4 weeks before increasing

When	Dose	Draw	How often
0.25 mg	250 mcg	5 units	once weekly
0.5 mg	500 mcg	10 units	once weekly
0.75 mg	750 mcg	15 units	once weekly
1 mg	1 mg	20 units	once weekly
1.25 mg	1.25 mg	25 units	once weekly
1.5 mg	1.5 mg	30 units	once weekly
1.75 mg	1.75 mg	35 units	once weekly
2 mg	2 mg	40 units	once weekly
2.25 mg	2.25 mg	45 units	once weekly
2.5 mg	2.5 mg	50 units	once weekly

Protocol

Peptide in vial (mg)

Bacteriostatic water (mL)

Target dose

Syringe size

Draw to

5units

on a 1 mL insulin syringe

0102030405060708090100

5 mg in 1 mL is 5 mg/mL, or 50 mcg per unit. Draw 5 units (0.05 mL) for 250 mcg.

Volume per dose

0.05 mL

Concentration

5 mg/mL

Doses per vial

Who should avoid it

Anyone allergic or hypersensitive to any of the ingredients.
Anyone pregnant or breastfeeding.
Anyone with thyroid disease.
Anyone who has, or whose family has, a history of medullary thyroid cancer — a cancer of specific hormone-producing cells in the thyroid gland. The FDA requires a boxed warning about this on all semaglutide products.
Anyone with Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2), an inherited condition that raises the risk of tumours in several hormone glands.
Anyone with gallbladder disease or pancreatitis (inflammation of the pancreas).
Care needed with a past history of pancreatitis — stop and seek medical advice if pancreatitis is suspected.
Care needed with diabetic retinopathy (damage to the blood vessels at the back of the eye), because fast improvement in blood sugar control can make it worse. Talk to your doctor first.
Care needed with kidney disease — vomiting and diarrhoea can dry you out and injure the kidneys. Medical supervision is essential and staying hydrated is critical.
Care needed with gastroparesis (very slow stomach emptying) or other gut movement disorders.
Care needed with depression or a history of suicidal thoughts. Large reviews did not show increased risk in people without existing mental health conditions, but there is little data in people with active major depression.
Talk to your doctor first if you have hypoglycaemia — low blood sugar.
Talk to your doctor first if you have chronic eye disease.
Talk to your doctor first if you have severe digestive disorders.
If you are on insulin or sulfonylureas (a class of diabetes tablet), those doses may need to be lowered to prevent low blood sugar. This needs medical supervision.
Tell your surgeon or anaesthetist. The American Society of Anesthesiologists recommends holding GLP-1 agonists for at least one week before elective surgery, because food can stay in the stomach longer than expected.

Known hypersensitivity to semaglutide or any component.
Current pregnancy or breastfeeding.
Thyroid disease.
Personal or family history of medullary thyroid carcinoma (MTC). Rodent studies showed thyroid C-cell tumours including MTC; human relevance is unestablished, but the FDA mandates a boxed warning and the contraindication stands.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Gallbladder disease or pancreatitis. Class-level meta-analysis shows a 37% increased risk of gallbladder or biliary disease; semaglutide trial meta-analyses did not show increased acute pancreatitis risk (OR 0.7, 95% CI 0.5 to 1.2) but it remains a listed precaution and should be discontinued if pancreatitis is suspected.
Caution: diabetic retinopathy — rapid glycaemic improvement can worsen retinopathy.
Caution: renal impairment — dehydration-related acute kidney injury secondary to gastrointestinal losses has been reported despite the FLOW renal-outcome benefit.
Caution: gastroparesis or other gastrointestinal motility disorders.
Caution: depression or history of suicidal ideation. A review of 91 placebo-controlled trials in over 107,000 patients found no increased risk, and in 2025 the FDA requested removal of the ideation warning, but patients with active major depressive disorder or prior attempts were not extensively studied.
Physician consultation required first: hypoglycaemia.
Physician consultation required first: chronic eye disease.
Physician consultation required first: severe gastrointestinal disorders.
Drug interaction: insulin and sulfonylureas may require dose reduction to prevent hypoglycaemia; medical supervision required.
Drug interaction: prokinetics (metoclopramide, erythromycin) may counteract the gastric motility effect. No clinically significant interaction found with metformin, warfarin, atorvastatin or digoxin; delayed gastric emptying could theoretically alter oral contraceptive absorption timing.
Perioperative: hold for at least 1 week before elective procedures under anaesthesia (American Society of Anesthesiologists guidance) because of aspiration risk from delayed gastric emptying.

Side effects

Of all the GLP-1 medications, this one has one of the highest rates of side effects. In the SURMOUNT-5 head-to-head trial, 5.6% stopped semaglutide because of gut side effects versus 2.7% on tirzepatide.
Nausea — 44% of users versus 17% on placebo. It is the most discussed side effect and is usually worst in the first 1 to 2 weeks after each dose increase, then fades.
Diarrhoea — 32% versus 16% on placebo.
Vomiting.
Constipation, reported almost as often as nausea, especially at higher doses. Users manage it with magnesium citrate, more water and fibre.
Abdominal pain.
Headache.
Fatigue and low energy, common in the first few months and often linked to eating too little food or protein rather than the drug itself.
Dizziness.
Sulphur-smelling burps, thought to come from food sitting in the stomach longer.
Gas and bloating.
Heartburn or acid reflux.
Runny nose.
Sore throat.
Injection site reactions.
Hair shedding (telogen effluvium) — 2.5% versus 1.0% on placebo, and more likely with bigger weight loss. Women appear to be at higher risk.
Facial fat loss, widely called "Ozempic face". It happens with any fast weight loss but is more noticeable here.
Mood changes — some users report more anxiety, irritability or feeling emotionally flat.
About 4.5% of people in STEP-1 stopped because of gut side effects.
Less common but more serious — gallbladder disease. As a class, GLP-1 agonists carry a 37% higher risk of gallbladder or biliary disease, with gallstones up 27% and gallbladder inflammation up 36%.
Less common but more serious — inflammation of the pancreas.
Less common but more serious — thyroid tumours and/or cancer.
Less common but more serious — gastroparesis, meaning the stomach empties far too slowly. Most cases settle after stopping, but the FDA has received reports of cases that had not resolved. Contact a medical provider for lasting nausea, vomiting or severe bloating.
Less common but more serious — kidney failure.
Less common but more serious — changes in vision, especially in people with diabetes.
Less common but more serious — depression or suicidal thoughts.
Less common but more serious — increased heart rate.
Less common but more serious — hypoglycaemia (low blood sugar), especially if combined with insulin or sulfonylureas.

Highest side-effect burden of the GLP-1 class. SURMOUNT-5 discontinuation for gastrointestinal events: 5.6% semaglutide versus 2.7% tirzepatide.
Nausea 44% versus 17% placebo; dose-dependent, worst in the 1 to 2 weeks following each titration step and typically improving after the first 4 to 8 weeks. Slow titration substantially reduces severity.
Diarrhoea 32% versus 16% placebo.
Vomiting.
Constipation — reported nearly as frequently as nausea and dose-dependent.
Abdominal pain.
Headache.
Fatigue, frequently attributable to inadequate caloric and protein intake rather than a direct drug effect.
Dizziness.
Sulfurous eructation, attributed to delayed gastric emptying.
Flatulence and bloating.
Heartburn and acid reflux.
Rhinorrhoea.
Sore throat.
Injection site reactions.
Telogen effluvium 2.5% versus 1.0% placebo, correlating with magnitude of weight loss; risk may be higher in women.
Pronounced facial fat loss with rapid weight loss ("Ozempic face"), not compound-specific.
Mood changes: anxiety, irritability, emotional blunting reported anecdotally.
Gastrointestinal discontinuation rate in STEP-1: approximately 4.5%.
Gallbladder and biliary disease: class-level RR 1.37 (95% CI 1.23 to 1.52) across 76 RCTs; cholelithiasis +27%, cholecystitis +36%, higher at higher doses and in weight-loss trials, plausibly mediated by rapid weight loss.
Pancreatitis: meta-analyses show no increased risk versus placebo (OR 0.7, 95% CI 0.5 to 1.2); remains a listed precaution and discontinuation trigger.
Thyroid tumours and/or carcinoma: rodent C-cell tumours drive the boxed warning; a systematic review of 10 RCTs in 14,550 participants found notably low thyroid cancer incidence, isolated cases under 1% within study groups.
Gastroparesis: clinically significant delayed gastric emptying, mostly resolving after discontinuation, with FDA reports of unresolved cases at time of reporting.
Renal failure; acute kidney injury case reports primarily secondary to dehydration from gastrointestinal losses.
Visual changes, particularly in diabetics with retinopathy.
Depression or suicidal ideation — FDA review of 91 placebo-controlled trials in over 107,000 patients found no increased risk, and the class labelling warning was requested to be removed in 2025.
Increased heart rate.
Hypoglycaemia, particularly with concurrent insulin or sulfonylureas.

What the evidence shows

Semaglutide has one of the biggest bodies of human research of any weight loss drug.

STEP-1 (Wilding et al., 2021) gave 1,961 adults with obesity and without diabetes either 2.4 mg weekly or placebo for 68 weeks. Average weight loss was 14.9% versus 2.4% on placebo. 86% lost at least 5% of body weight, 69% lost at least 10%, and 50% lost at least 15%. For someone starting at 240 pounds, 15% is roughly 36 pounds.

STEP-3 (Wadden et al., 2021) added intensive behaviour therapy and a starting low-calorie diet in 611 adults: 16.0% weight loss at 68 weeks versus 5.7% with placebo plus therapy, and about 40% lost 20% or more.

STEP-5 (Garvey et al., 2022) followed 304 adults for 2 years and weight loss was held at 15.2% at 104 weeks with continued treatment.

STEP-1 Extension (Wilding et al., 2022) followed 327 people for a year after stopping. Those who had lost an average of 17.3% regained two-thirds of it, finishing 5.6% below where they started.

For the heart, the SELECT trial (Lincoff et al., 2023) enrolled 17,604 people aged 45 and older with existing heart disease and a BMI of 27 or more, without diabetes. Over a mean 39.8 months, major heart events — heart attack, stroke or cardiovascular death — dropped by 20%. For the kidneys, the FLOW trial cut important kidney outcomes by 24% in people with type 2 diabetes and chronic kidney disease over a median 3.4 years.

On body composition, a DXA analysis of 140 STEP-1 participants found fat mass down 19.3% and visceral fat down 27.4%, with lean mass down 9.7%. Lean mass as a share of total body mass actually rose by 3.0 percentage points because fat fell faster. Roughly 60 to 65% of the weight lost was fat and 35 to 40% was lean tissue. The SEMALEAN study (Alissou et al., 2025) followed 106 patients for 12 months: fat mass fell 18%, lean mass fell 3 kg by 7 months and then stabilised, grip strength improved by 4.5 kg, and sarcopenic obesity fell from 49% to 33%.

Against newer compounds, SURMOUNT-5 (Aronne et al., 2025) compared 751 adults head to head. At 72 weeks tirzepatide produced 20.2% weight loss versus semaglutide's 13.7%.

Semaglutide is supported by one of the largest Phase 3 programmes in obesity medicine, plus a 17,604-patient cardiovascular outcomes trial.

STEP-1 (Wilding et al., 2021): 1,961 adults with obesity, without diabetes, 2.4 mg weekly versus placebo for 68 weeks. Mean weight loss 14.9% versus 2.4%; 86% achieved at least 5%, 69% at least 10%, 50% at least 15%. New England Journal of Medicine.

STEP-3 (Wadden et al., 2021): 611 adults, semaglutide plus intensive behavioural therapy 16.0% versus 5.7% with placebo plus therapy at 68 weeks; approximately 40% lost 20% or more. JAMA.

STEP-5 (Garvey et al., 2022): 304 adults without diabetes, 15.2% maintained at 104 weeks on continued treatment. Nature Medicine. The weight loss curve plateaued around 12 to 15 months at approximately 15%.

STEP-1 Extension (Wilding et al., 2022): 327 participants followed one year post-withdrawal; two-thirds of the mean 17.3% loss regained, net 5.6% from baseline. Diabetes, Obesity and Metabolism.

SELECT (Lincoff et al., 2023): 17,604 patients aged 45 and older with established cardiovascular disease and BMI 27 or greater, without diabetes. MACE reduced 20% (HR 0.80, 95% CI 0.72 to 0.90, P < 0.001) over mean 39.8 months. New England Journal of Medicine.

FLOW: 24% reduction in clinically important kidney outcomes in type 2 diabetes with chronic kidney disease over median 3.4 years, suggesting renoprotection beyond weight loss alone.

Body composition: exploratory DXA analysis of STEP-1 (140 participants) showed total fat mass −19.3%, regional visceral fat −27.4%, total lean body mass −9.7% in absolute terms, with lean mass proportion rising 3.0 percentage points. Approximately 60 to 65% of weight lost was fat, 35 to 40% lean; the higher end of lean loss (39 to 45%) is cited from the broader STEP-1 data. SEMALEAN (Alissou et al., 2025): 106 patients on 2.4 mg for 12 months, fat mass −18% at 12 months, lean mass −3 kg at 7 months then stabilising, handgrip strength +4.5 kg at 12 months, sarcopenic obesity prevalence 49% to 33%.

Comparative: SURMOUNT-5 (Aronne et al., 2025), 751 adults, 72 weeks — tirzepatide 20.2% versus semaglutide 13.7%, a 47% relative difference, with gastrointestinal discontinuation higher on semaglutide (5.6% versus 2.7%). Retatrutide in Phase 3 TRIUMPH-4 produced 28.7% at 68 weeks at 12 mg, consistent with triple-receptor coverage; retatrutide is roughly 40% as potent as semaglutide at GLP-1 but nine times more potent at GIP with added glucagon receptor activation.

Safety literature: gallbladder/biliary risk RR 1.37 across 76 RCTs; pancreatitis OR 0.7 (95% CI 0.5 to 1.2); thyroid cancer incidence notably low across 10 RCTs in 14,550 participants; no increased suicidal ideation across 91 placebo-controlled trials in over 107,000 patients.

User reports

From public forums

These reports come from public platforms including Reddit, peptide forums and published analyses of patient experiences. They are anecdotal and do not carry the weight of published research.

Users commonly report losing 8 to 18% of body weight within 6 to 12 months. Many describe the appetite suppression as dramatic, especially at higher doses. The most consistent theme is that food simply becomes less interesting, rather than needing willpower to resist it.

Nausea is by far the most discussed side effect, particularly during dose increases. Most users say it is worst in the first 1 to 2 weeks after each step up and then fades. Common ways people manage it: smaller meals, avoiding fatty food, drinking plenty of water, and not lying down after eating. Constipation is reported almost as often, especially at higher doses, and users say fibre, magnesium and hydration help but do not always fix it.

"Ozempic face" is widely discussed. Losing a lot of weight quickly can thin the face and make it look gaunt or older. Some users, particularly women, report hair shedding.

Muscle loss is the biggest concern among people who also train. Many report feeling weaker and losing muscle definition, especially if protein intake is low. The people reporting the best outcomes describe aggressive protein targets — at least 1 gram per pound of goal body weight — regular resistance training, and treating both as non-negotiable even when appetite is suppressed and eating feels like a chore.

A growing number of users discuss switching to tirzepatide or retatrutide, usually wanting more weight loss or better muscle preservation. Those switching to retatrutide often note that appetite suppression feels weaker, which is expected given its lower GLP-1 potency.

Aggregated from Reddit, peptide forums and published qualitative analyses of patient experience. Anecdotal, and weighted accordingly.

Reported weight loss clusters at 8 to 18% of body weight within 6 to 12 months, with appetite suppression described as dramatic at higher doses. The recurring qualitative signature is reduced food salience rather than active restraint — consistent with the dopaminergic reward-modulation arm of GLP-1 signalling.

Nausea dominates the side-effect discussion and is titration-linked, typically peaking in the 1 to 2 weeks after each escalation. Practical mitigations reported: smaller meals, low-fat meals, hydration, avoiding recumbency after eating. Constipation is near-equal in frequency and dose-dependent; magnesium citrate, fluid and fibre are the usual countermeasures. Fatigue and low energy are frequently reported in the early months and often trace to inadequate caloric and protein intake rather than a direct drug effect. Sulfurous eructation is widely described and attributed to delayed gastric emptying. Some users report anxiety, irritability or emotional blunting.

Facial volume loss ("Ozempic face") reflects the rate of weight loss rather than anything compound-specific. Telogen effluvium is reported, more often by women, consistent with the 2.5% versus 1.0% trial incidence.

Lean mass loss is the dominant concern in training populations. Reports of reduced strength and definition cluster in users not hitting protein targets; best-outcome reports consistently describe at least 1 gram of protein per pound of goal body weight, resistance training 2 to 3 days per week, and treating both as fixed even under suppressed appetite.

Switching to tirzepatide or retatrutide is an increasing theme, motivated by greater weight loss, better lean mass preservation and multi-receptor metabolic effects. Users moving to retatrutide frequently report weaker appetite suppression, which is expected from its deliberately reduced GLP-1 potency traded for glucagon receptor activation.

User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.

Stacking

Resistance training and protein
Not a peptide stack, but the single most important thing to combine with this compound. Without lifting and enough protein, 35 to 40% of the weight lost will be lean tissue. With resistance training 2 to 3 days per week and at least 1 gram of protein per pound of goal body weight daily, that ratio improves a lot. A published case series documented one patient who lost 33% of body weight with only 6.9% muscle loss, and another who gained 2.5% muscle while losing 26.8% of body weight, both with consistent training and protein.
The primary non-pharmacological co-intervention. Untrained, protein-deficient use yields 35 to 40% of total weight lost as lean mass; resistance training 2 to 3 days per week plus at least 1 g protein per pound of goal body weight materially shifts that ratio. A published case series documented 33% total body weight loss with only 6.9% muscle loss, and a second case gaining 2.5% muscle across a 26.8% body weight reduction, both with consistent training and protein intake.
AOD-9604
Improves fat loss, supports body recomposition, and helps break through plateaus while on GLP1-S.
Adds a direct lipolytic arm to the appetite-driven deficit — the designated plateau breaker and recomposition support, relevant because semaglutide itself has no fat-oxidation mechanism.
L-Carnitine
Enhances energy and fat burning. Especially helpful if fatigue is one of the side effects showing up.
Enhances fat oxidation and energy, targeted at the fatigue that features prominently in both trial and anecdotal side-effect reporting.
NAD+
Supports repair of the mitochondria — the parts of your cells that make energy — and boosts metabolism and cellular energy.
Mitochondrial repair support with a metabolic and cellular-energy boost, offsetting the energy cost of a sustained deficit.
BPC-157
No interaction concerns and completely different mechanisms, so it can be run at the same time with no timing conflicts. It is paired with TB-500 to reduce gut inflammation, promote healing and improve resilience while eating less. Some users report it helps with the gut discomfort, though no published data supports that specific use.
No interaction concerns; entirely separate mechanisms and no timing conflict when run concurrently. Paired with TB-500 for gut inflammation, healing and systemic resilience under caloric restriction — directly relevant given the gastrointestinal side-effect profile. Anecdotal reports of relief from semaglutide-related GI discomfort are unsupported by published data for that application.
TB-500
Listed alongside BPC-157 for the same purpose: less gut inflammation, better healing, better resilience during calorie restriction. No interaction concerns.
The paired healing agent with BPC-157 for gut inflammation and systemic resilience under caloric restriction. No interaction concerns, different mechanism, concurrent dosing acceptable.
CJC-1295 / Ipamorelin
Preserves lean muscle and supports growth hormone signalling, which makes weight loss safer and more sustainable. No interaction concerns, but the timing differs: growth hormone peptides need a fasted window and GLP1-S does not. The appetite suppression can actually make that fast easier.
Preserves lean mass and supports GH signalling through the deficit — the standard counter to lean-tissue loss during rapid GLP-driven weight loss. No interaction concerns, but GH secretagogues (CJC-1295, ipamorelin, sermorelin) require a fasted window while semaglutide does not; suppressed appetite typically makes that fasting window easier to hold.
Testosterone replacement therapy (TRT)
No interaction concerns, and it can be run alongside. Some clinicians deliberately combine them because keeping testosterone levels up may help hold on to lean mass during weight loss.
No interaction concerns; concurrent use is routine. Some clinicians combine deliberately on the rationale that maintained androgen levels support lean mass retention during GLP-1-driven weight loss.
Glutathione
Supports liver function, the body's detox pathways, and reduces inflammation throughout the body.
Hepatic and detoxification pathway support with a systemic anti-inflammatory contribution.
Pancragen
May help reduce desensitisation — the loss of effect that can develop with long-term use.
Noted as potentially reducing receptor desensitisation in long-term users.
Other GLP-1 agonists — do not combine
Do not stack this with tirzepatide, retatrutide or any other GLP-1 medication. They act on the same target, so combining them raises side-effect risk without extra benefit and makes dosing impossible to manage. To switch, take the last GLP1-S dose and start the new compound the following week. No washout is needed.
Contraindicated as a combination: tirzepatide, retatrutide and other GLP-1 agonists share the same receptor, so co-administration compounds side-effect risk without proportional benefit and makes dose attribution impossible. Transition protocol is a final semaglutide dose followed by initiation of the new compound the following week; no washout required.
Insulin or sulfonylureas
If you are on insulin or sulfonylurea tablets for diabetes, those doses may need lowering when starting GLP1-S to prevent low blood sugar. This needs medical supervision.
Concurrent insulin or sulfonylurea therapy may require dose reduction on initiation to prevent hypoglycaemia. Requires medical supervision; semaglutide's insulinotropic effect is glucose-dependent and rarely hypoglycaemic alone, but additive risk with these agents is real.

Common questions

Does semaglutide burn fat directly?

No. It does not burn fatty acids and it does not speed up your metabolism. All of the weight loss comes from appetite suppression that makes it easier to eat less than you burn. That calorie deficit is what causes the fat loss. The drug just makes the deficit easier to stick to, because you are not fighting hunger all day.

No. There is no fatty acid oxidation mechanism and no increase in metabolic rate. Weight loss is entirely downstream of central appetite suppression producing a sustained caloric deficit. The compound reduces the behavioural cost of maintaining that deficit; it does not act on the energy expenditure side of the equation. Retatrutide, via glucagon receptor activation, is the only compound in the class that does.

Will the weight come back after stopping?

The data says most people regain two-thirds of the lost weight within one year of stopping. In the STEP-1 extension, people who had lost an average of 17.3% regained two-thirds, ending 5.6% below their starting weight. It is not inevitable. The people who keep the weight off use the appetite suppression window to build real habits: protein targets, resistance training and sleep. The drug buys time; what happens in that time decides whether the result lasts.

STEP-1 Extension (Wilding et al., 2022) followed 327 participants for one year post-withdrawal: two-thirds of the mean 17.3% loss was regained, net 5.6% from baseline. This reflects the return of the underlying drivers of overeating once central appetite suppression is removed, compounded by the fact that most trial participants had not established the nutritional and training habits needed to hold the deficit unaided. Regain is not obligate, but it is the default without habit consolidation during the treatment window.

How does it compare to tirzepatide?

In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks — about 47% more weight loss. Tirzepatide acts on two targets rather than one, and that second target appears to help preserve more muscle. Interestingly, gut side effects that forced people to stop were actually more common on semaglutide (5.6%) than tirzepatide (2.7%).

SURMOUNT-5 (Aronne et al., 2025), 751 adults with obesity without diabetes, 72 weeks: tirzepatide 20.2% versus semaglutide 13.7%, a 47% relative difference. Tirzepatide is a dual GLP-1/GIP agonist; GIP activation appears to improve nutrient partitioning and may preserve more lean mass. Gastrointestinal discontinuation was higher on semaglutide (5.6% versus 2.7%).

How does it compare to retatrutide?

Retatrutide acts on three targets instead of one. In the Phase 3 TRIUMPH-4 trial it produced 28.7% weight loss at 68 weeks at the 12 mg dose. It is deliberately built with weaker GLP-1 action — about 40% as strong as semaglutide there — but nine times stronger at a second target, plus a third one that raises energy burn and drives liver fat use. It is the only compound in this class that affects how much energy you burn, not just how much you eat. It is not yet FDA approved and is expected to file in late 2026 or early 2027.

Retatrutide is a triple agonist at GLP-1, GIP and glucagon receptors. Phase 3 TRIUMPH-4 produced 28.7% weight loss at 68 weeks on 12 mg. It is intentionally designed with reduced GLP-1 potency — approximately 40% that of semaglutide — but nine-fold greater GIP potency plus glucagon receptor activation, which increases energy expenditure and drives hepatic fat oxidation. It is the only compound in the class acting on the expenditure side rather than intake alone. Not yet FDA approved; filing expected late 2026 or early 2027.

How much muscle will be lost?

In the STEP-1 DXA analysis, total lean mass fell 9.7%, making up 35 to 40% of the total weight lost. That number is not fixed. Enough protein and regular lifting improve the ratio a lot. Treat protein like a prescription: 1 gram per pound of your goal body weight every day, and lift weights at least 2 to 3 times a week. The SEMALEAN study also suggests lean mass loss levels off over time — lean mass fell 3 kg by 7 months then stabilised, and grip strength improved by 4.5 kg at 12 months.

STEP-1 DXA analysis: total lean body mass −9.7% absolute, accounting for 35 to 40% of total weight lost, while lean mass as a proportion of body mass rose 3.0 percentage points because fat mass fell further (−19.3% total, −27.4% visceral). The ratio is modifiable: adequate protein intake (at least 1 g per pound of goal body weight) plus resistance training 2 to 3 times weekly substantially improves it. SEMALEAN (Alissou et al., 2025) suggests plateauing of lean loss — −3 kg at 7 months then stabilisation, with handgrip strength +4.5 kg at 12 months and sarcopenic obesity prevalence falling from 49% to 33%.

Is it safe for the kidneys?

The FLOW trial showed a 24% reduction in important kidney outcomes in people with type 2 diabetes and chronic kidney disease. However, there are case reports of sudden kidney injury, mostly caused by dehydration from nausea, vomiting and diarrhoea. If kidney disease is already present, medical supervision is essential and staying hydrated is critical.

FLOW demonstrated a 24% reduction in clinically important kidney outcomes in type 2 diabetes with chronic kidney disease over median 3.4 years, suggesting renoprotection beyond weight loss. Countervailing: case reports of acute kidney injury exist, predominantly secondary to volume depletion from gastrointestinal adverse effects. Pre-existing renal impairment mandates medical supervision and aggressive attention to hydration.

Can it cause hair loss?

Hair shedding (telogen effluvium) was reported in 2.5% of trial participants versus 1.0% on placebo. It appears to be linked to how much weight is lost rather than a direct effect of the drug — fast weight loss is a known trigger for this kind of shedding. The risk may be higher in women.

Telogen effluvium incidence 2.5% versus 1.0% placebo in trial data. The pattern tracks magnitude of weight loss rather than a direct pharmacological effect; rapid weight loss is an established trigger. Risk appears elevated in women.

Does a surgeon or anaesthetist need to be told?

Yes. Because the stomach empties more slowly, food can still be present even after standard fasting before an operation. The American Society of Anesthesiologists recommends holding GLP-1 agonists for at least one week before elective surgery, to reduce the risk of stomach contents entering the lungs under anaesthetic.

Yes. Delayed gastric emptying means residual gastric contents can persist beyond standard preoperative fasting windows. The American Society of Anesthesiologists recommends holding GLP-1 agonists for at least one week before elective surgery to reduce aspiration risk under anaesthesia.

References

This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.